How HDM1002 interacts with common drugs and diabetes medications
This study tests how a new drug called HDM1002 interacts with common diabetes medications (metformin, empagliflozin) and other drugs like warfarin and valsartan. If you are a generally healthy adult (age 18-45) with a higher BMI, this trial helps ensure the new drug is safe when taken with other medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old.
- You need to be in good general health, with no major medical problems.
- Your weight must be at least 110 pounds, and your body mass index (BMI) between 24 and 35.
- You cannot have a personal or family history of certain thyroid cancers or related genetic conditions.
- You must not have had pancreatitis, gallbladder attacks, or serious hypoglycemia in the last 3 months.
- You cannot have any condition that increases bleeding risk or affects stomach absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new medicine, HDM1002, interacts with four common drugs (repaglinide, atorvastatin, digoxin, rosuvastatin) in healthy and overweight adults. The results will help guide safe dosing for future patients.
This study tests how a new medication (HDM1005) affects the way your body absorbs and processes common drugs like metformin, atorvastatin, warfarin, and digoxin. It is for healthy volunteers to understand potential interactions before further testing.
This study tests how a new drug (HDM1002) interacts with two other common medicines—rifampin and itraconazole—in healthy volunteers. The results will help doctors understand how to safely use the drug with other medications.
This study looks at how the drug HDM1002 is absorbed by the body, both when taken with food and on an empty stomach. It helps researchers understand the best way to take the medication.
This trial tests a new medicine called HDM1005 for people with type 2 diabetes who haven't been helped enough by diet and exercise alone, and who haven't taken any diabetes medication in the last 12 weeks. It aims to see if the medicine can help lower blood sugar levels safely.
This trial tests an investigational drug called HDM1005 for people with type 2 diabetes whose blood sugar is still high despite taking metformin (with or without another diabetes pill called an SGLT2 inhibitor). The goal is to see if the new drug can better lower blood sugar levels.
Hear when a new Overweight Subject trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.